Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.

Journal of the American College of Cardiology
Mona FiuzatChristopher M O'Connor

Abstract

This study sought to examine the association between baseline beta-blocker (BB) dose and outcomes in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. Beta-blockers reduce morbidity and mortality in chronic heart failure (HF) patients with reduced ejection fraction, but it is unclear whether titrating to higher BB doses improves outcomes in this setting. The HF-ACTION trial was a randomized, multicenter trial enrolling 2,331 ambulatory HF patients with systolic dysfunction (New York Heart Association functional class II to IV, left ventricular ejection fraction <0.35) randomized to exercise training versus usual care, with median follow-up of 2.5 years. The BB dose at baseline was standardized with carvedilol equivalents and analyzed as a continuous variable and by discrete dose groups. The relationship between BB dose and the primary endpoint of all-cause mortality or all-cause hospitalization and other cardiovascular secondary endpoints was determined before and after adjustment for variables significantly associated with outcomes in the HF-ACTION cohort. Ninety-five percent of patients were receiving a BB. There was a significant inverse relationship between BB dose and all-...Continue Reading

References

Sep 1, 1990·The American Journal of Cardiology·S G PollockM L Smucker
Oct 4, 2005·European Journal of Heart Failure·Henry KrumJ A Kragten
Jan 24, 2007·American Heart Journal·David J WhellanUNKNOWN HF-ACTION Trial Investigators
Jul 1, 2008·Circulation. Heart Failure·Gregg C FonarowMary Norine Walsh
Jul 9, 2010·Journal of Cardiac Failure·UNKNOWN Heart Failure Society of AmericaMary N Walsh
Mar 25, 2011·European Journal of Heart Failure·Hans-Dirk DüngenUNKNOWN CIBIS-ELD investigators and Project Multicentre Trials in the Competence Network Heart Failure
Jun 7, 2011·American Heart Journal·Gregg C FonarowPaul A Heidenreich

❮ Previous
Next ❯

Citations

Oct 9, 2013·Heart Failure Reviews·Frederik H Verbrugge, Wilfried Mullens
Dec 12, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Antonino Di FrancoGaetano A Lanza
Dec 11, 2014·The New England Journal of Medicine·John J V McMurrayScott D Solomon
Oct 9, 2013·Arquivos brasileiros de cardiologia·Irineu Blanco MorenoAntônio Carlos Pereira-Barretto
Jan 20, 2015·BMC Cardiovascular Disorders·Filippo M SarulloGaetano A Lanza
Jun 15, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·M Obadah Al Chekakie
Nov 5, 2016·Pharmacogenomics·Fannie MottetSimon de Denus
Feb 25, 2017·European Journal of Heart Failure·Stefania PaolilloPiergiuseppe Agostoni
Sep 18, 2012·European Journal of Heart Failure·Kazuhiro YamamotoUNKNOWN J-DHF Investigators
Jun 21, 2019·ESC Heart Failure·Michael J DiamantNathaniel M Hawkins
Sep 13, 2013·American Journal of Physiology. Cell Physiology·Huiyin TuYu-Long Li
May 23, 2020·European Journal of Clinical Pharmacology·Sanjay VermaDavid E Lanfear
Aug 5, 2020·JAMA : the Journal of the American Medical Association·Sean P MurphyJames L Januzzi
Dec 11, 2014·The New England Journal of Medicine·Adam Timmis
Jun 11, 2016·European Journal of Heart Failure·Orly VardenyUNKNOWN Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF
Nov 7, 2018·European Journal of Preventive Cardiology·Joseph J CuthbertAndrew L Clark
Jan 24, 2020·Heart and Vessels·Kimiko NagaraNobuhisa Hagiwara
Mar 28, 2020·European Journal of Heart Failure·Ify R MordiChim C Lang
Dec 22, 2017·Pharmacotherapy·Kristin R SmithJo E Rodgers
Mar 20, 2016·Journal of Clinical Pharmacy and Therapeutics·A J AnsaraJ M Koehler
Jun 26, 2018·European Journal of Pharmacology·Dongze ZhangYu-Long Li
Mar 29, 2021·European Heart Journal. Cardiovascular Pharmacotherapy·Bin WangXin Zheng
Nov 4, 2021·Journal of the American Heart Association·Richard K ChengMathew S Maurer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.